Gain insights into Paysign, Inc.'s Q4 2024 performance, driven by 212% growth in patient affordability revenue.

The industry needs to embrace innovation with technology towards novel drug development to remain relevant in the marketplace.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

How continent is navigating decades-old obstacles to build robust vaccine industry ANALYSIS | The African Union has embarked ...

Emzor Pharmaceutical Industries Limited has revised its completion timeline for the $23 million active pharmaceutical ...

Highlighting deals by PE firms pursuing investments in marketing agencies focused on pharma and life sciences; insights on a ...

Ajay Bagga asserts that sectors such as gems, jewellery, electronics, and pharma could be hit by Trump's tariffs, affecting ...

Sessions highlighted the UAE’s significant investments in life sciences infrastructure, cold chain management ... we have ...

The ongoing conflicts between Ukraine and Russia, as well as Israel and Palestine, have sent ripples across various ...